Zimbabwe has turned down a substantial US healthcare agreement valued at $367m (£272m) spanning five years over Washington's demand for confidential biological samples.
This rejection came to light following a internal memorandum dated December was disclosed, indicating that Head of State Emmerson Mnangagwa felt the arrangement was "unbalanced".
An official spokesperson later stated that the US was requesting biological samples for scientific study and commercial purposes while was not willing to guarantee the benefits from future treatments.
"We will now turn to the challenging and unfortunate task of winding down our health aid in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont publicly.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe during the past two decades.
A doctors' association in Zimbabwe has urged more talks to secure a deal agreeable to all parties so the country's critical HIV treatment initiative can continue.
Wider Context
This development follows a comparable case in Kenya, where a high court blocked a related deal with the US after concerns were raised about the safety of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has slashed foreign aid and shut down the US Agency for International Development (USAID).
The agency had overseen aid for the American government, but Trump claimed its expenditure was "wasteful" and his government was pursuing direct bilateral agreements to enhance transparency and accountability.
According to reports, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Specifics of the Rejected Deal
This assistance for Zimbabwe was intended to funded "tackling HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered immense advantages for the people of Zimbabwe, particularly the 1.2 million men, women and children currently receiving HIV treatment through US-supported initiatives," Tremont commented.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"The proposal required Zimbabwe to provide its biological resources and data indefinitely, without any corresponding guarantee of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that shared data," he stated.
"Put simply, our country would provide the raw materials for medical research without any assurance that the final treatments would be available to our population if a new disease outbreak arise."
Sovereignty and Global Health
He also noted that the US's withdrawal from the World Health Organization (WHO) and its push of bilateral health agreements were undermining systems previously established through the international organization.
Mangwana cited its Pandemic Benefit-Sharing scheme designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a country contributes its information, the benefits – such as medicines and cures – are distributed fairly, not commercialised exclusively by those with the funds to create them."
Zimbabwe's reservations over the US deal "should not be misconstrued as opposition to America," Mangwana stressed.
"We encourage ongoing discussions with our American counterparts on how subsequent collaboration might be designed in a manner that respects the sovereignty and dignity of each country."
Health Experts Response
A leading public health body said it understood the official position, but suggested that talks need to persist considering much of the country's Aids initiatives were funded by external financing.
"In cases where technical issues exist, such as those involving data governance or implementation frameworks, these can frequently be resolved via technical clarification and mutually agreed protections," it added.
The situation emphasises the continuing debate between receiving vital international aid and safeguarding local interests in an ever more interconnected world.